Engraftment following transplantation of an HCT product is critically dependent upon infusion of a sufficient number (dose) of viable, functional hematopoietic stem/progenitor cells (HPC). Accordingly, although the total nucleated cell (TNC) and CD34+ cell content are the primary features that are used to determine whether an HCT product is suitable for transplantation, it is also vitally important to evaluate HPC viability and function. This is especially true when HCT processing is delayed, the HCT product is manipulated, the HCT product requires shipment over large geographic distances and/or the HCT product is cryopreserved. This session will provide a focused discussion of commonly used methods to assess TNC and HPC cell viability with specific emphasis placed on improving the general understanding of how different methods work, the advantages and limitations of different approaches, the practical details of implementing these methods in the cell therapy laboratory and the unique challenges encountered with attempts to standardize these techniques.

*CT Program

You will have the ability to purchase CD-ROMs of this Audioconference 2 weeks after the session has been presented. For any questions, please contact MultiviewMediaSupport@multiview.com.